BKM120 in Cancers With PIK3CA Activating Mutations
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Lung Cancer|Breast Cancer|Colorectal Cancer|Cholangiocarcinoma|Solid Tumors
Interventions: DRUG: BKM120
Sponsor: Massachusetts General Hospital
Collaborators: Novartis Pharmaceuticals